Ann: Azer-cel demonstrates two additional Complete Responses, page-265

As previously mentioned by @Mason14, the most advanced competitor to IMU in this space is Allogene Therapeutics who are conducting registrational clinical trial with primary and study completion estimated mid 2027 and mid 2031 likely due to their exclusion of DLBCL patient who hasn't failed a previous SoC treatment let alone 4-5 and they have 31 recruitment sites in the US, how IMU has design the clinical trial for Azer-Cel demonstrate more commercial viability and valuation and allow them to recruit those who have failed 4-5 treatments easier and also show Azer-Cel as far superior being able to treat patients in the worst condition possible for DLBCL sufferers.

But that is still 19 patients recruited over this period so how is that slow progress??? If they were able to include the Cohort A then IMU will have enough data to apply for registrational clinical trial. Cohort A didn't "flop", there were still 2 CR, 3 PR and 3 SD reported from the 12 patients but clearly IMU noticed the efficacy wasn't as expected within the duration which is why the clinical trial is now 6-8 months behind. Also, those 3 cohort B added since 5 months ago are evaluable patients and we know there's another patient recruited here last month after announcing sites was open in Australia 3 months ago so IMU might have the number of patients required to apply for registrational clinical trial but waiting on the data???

Recently you replied to me saying Azer-Cel is the IP with most interest and discounted the clinical trial updates for VAXINIA and OASIS expected to released in the next 2-4 months but you sold last month when the pps was near an all time low for the last14 months before this further positive clinical trial for Azer-Cel. And say you have no regret but posted that post with the incorrect expenditure and "slow" progress.....I'm not buying it.